Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
AnaptysBio (NASDAQ:ANAB) announced a virtual investor event scheduled for October 14, 2025, at 4:30 PM ET to discuss ANB033, their CD122 antagonist therapeutic candidate. The presentation will feature Dr. Joseph A. Murray from Mayo Clinic alongside the company's management team.
The event will cover three key areas: ANB033's mechanism of action as a CD122 receptor antagonist, preclinical and initial Phase 1a data from healthy volunteers, and celiac disease biology along with Phase 1b trial design. A Q&A session will follow the presentation, with a live webcast available on the company's investor relations website.
AnaptysBio (NASDAQ:ANAB) ha annunciato un evento virtuale per investitori previsto per 14 ottobre 2025 alle 16:30 ET per discutere ANB033, candidato terapeutico antagonista di CD122. La presentazione vedrà la partecipazione del Dr. Joseph A. Murray della Mayo Clinic insieme al team dirigenziale dell'azienda.
L'evento affronterà tre temi principali: il meccanismo d'azione di ANB033 come antagonista del recettore CD122, i dati preclinici e le prime evidenze di Fase 1a provenienti da volontari sani e la biologia della celiachia, insieme al design dello studio di Fase 1b. A seguire una sessione di domande e risposte, con una diretta webcast disponibile sul sito di relazioni con gli investitori dell'azienda.
AnaptysBio (NASDAQ:ANAB) anunció un evento virtual para inversores programado para el 14 de octubre de 2025 a las 4:30 PM ET para discutir ANB033, su candidato terapéutico antagonista de CD122. La presentación contará con el Dr. Joseph A. Murray de la Mayo Clinic junto al equipo directivo de la empresa.
El evento cubrirá tres áreas clave: el mecanismo de acción de ANB033 como antagonista del receptor CD122, datos preclínicos y los primeros datos de Fase 1a en voluntarios sanos, y la biología de la enfermedad celíaca junto con el diseño del ensayo de Fase 1b. Habrá una sesión de preguntas y respuestas tras la presentación, y se podrá ver en directo a través de la página de relaciones con inversores de la empresa.
AnaptysBio (NASDAQ:ANAB)가 2025년 10월 14일 동부 표준시 오후 4시 30분에 예정된 가상 투자자 이벤트를 발표했습니다. 이 이벤트는 CD122 길항제 치료 후보 ANB033에 대해 논의하며, Mayo Clinic의 Joseph A. Murray 박사와 회사 경영진이 함께 발표합니다.
행사에서는 세 가지 핵심 주제를 다룹니다: CD122 수용체 길항제로서의 ANB033의 작용 기전, 건강한 지원자 대상의 전임상 및 1a상 초기 데이터, 셀리악병 생물학과 1b상 설계. 발표 후 Q&A 세션이 이어지며, 회사의 투자자 관계 웹사이트에서 라이브 webcast를 시청할 수 있습니다.
AnaptysBio (NASDAQ:ANAB) a annoncé un événement virtuel destiné aux investisseurs prévu le 14 octobre 2025 à 16h30 HE pour discuter d’ANB033, leur candidat thérapeutique antagoniste du CD122. La présentation mettra en vedette le Dr. Joseph A. Murray de la Mayo Clinic aux côtés de l’équipe de direction de l’entreprise.
L’événement couvrira trois axes clés: le mécanisme d’action d’ANB033 en tant qu’antagoniste du récepteur CD122, les données précliniques et les premiers résultats de la Phase 1a chez des volontaires sains, et la biologie de la maladie cœliaque ainsi que la conception de l’essai de Phase 1b. Une session de questions-réponses suivra la présentation, avec une webdiffusion en direct disponible sur le site des relations investisseurs de l’entreprise.
AnaptysBio (NASDAQ:ANAB) hat eine virtuelle Investorenveranstaltung angekündigt, die am 14. Oktober 2025 um 16:30 Uhr Eastern Time stattfinden wird, um ANB033, ihren CD122-Antagonisten-Kandidaten, zu besprechen. Die Präsentation wird von Dr. Joseph A. Murray von der Mayo Clinic neben dem Management des Unternehmens gehalten.
Die Veranstaltung deckt drei Kernbereiche ab: den Wirkmechanismus von ANB033 als CD122-Rezeptor-Antagonist, präklinische und erste Phase-1a-Daten von gesunden Probanden sowie die Biologie der Zöliakie zusammen mit dem Design der Phase-1b-Studie. Es folgt eine Q&A-Sitzung nach der Präsentation, und ein Livestream ist auf der Investor-Relations-Webseite des Unternehmens verfügbar.
أنابتيزبايو (ناسداك: ANAB) أعلنت عن حدث افتراضي للمستثمرين مُحدد ليوم 14 أكتوبر 2025 في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة ANB033، مرشحها العلاجي كمنافس لمستقبل CD122. ستشارك الدكتور جوزيف أ. موري من Mayo Clinic مع فريق إدارة الشركة في العرض.
سيغطي الحدث ثلاثة محاور رئيسية: آلية عمل ANB033 كمنافس لمستقبل CD122، بيانات ما قبل السريرية وبيانات المرحلة 1a الأولية من المتطوعين الأصحاء، وعلم بيولوجيا داء السيلياك مع تصميم تجربة المرحلة 1b. ستليها جلسة أسئلة وأجوبة، مع بث حي متاح على موقع علاقات المستثمرين الخاص بالشركة.
AnaptysBio (NASDAQ:ANAB) 宣布将于 2025年10月14日美国东部时间下午4:30举行线上投资者活动，讨论其 CD122 拮抗剂候选药物 ANB033。此次演示将由 Mayo Clinic 的 Joseph A. Murray 博士 与公司管理团队共同出席。
活动将覆盖三个重点领域：ANB033 作为 CD122 受体拮抗剂的作用机制、在健康志愿者中的前临床和初步 Phase 1a 数据，以及乳糜泻生物学及 Phase 1b 试验设计。演示结束后将进行问答环节，投资者 relations 网站提供现场网络直播。
- None.
- None.
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14.
The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along with members of the Anaptys management team.
The event will cover:
- ANB033’s mechanism of action, an antagonist of the CD122 receptor
- Preclinical data and initial Phase 1a data in healthy volunteers
- Celiac disease (CeD) disease biology and Phase 1b trial design
The event will be followed by a Q&A session.
A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available following the event.
About ANB033
ANB033, a potentially best-in-class CD122 antagonist, targets CD122, the common beta subunit of IL-15 and IL-2, to reduce NK cells and subsets of cytotoxic CD8+ and CD4+ T cells that are dependent on IL-15 and/or IL-2 for their maintenance, and survival and pathogenic activity. Anaptys has initiated a Phase 1b cohort in an initial indication, celiac disease.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio's (ANAB) virtual investor event for ANB033?
What will be discussed at AnaptysBio's ANB033 investor event?
Who will be presenting at the ANAB investor event?
How can investors access AnaptysBio's ANB033 presentation?
